Sage Therapeutics (SAGE) Expected to Announce Quarterly Earnings on Tuesday

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) is projected to release its earnings data after the market closes on Tuesday, February 11th. Analysts expect Sage Therapeutics to post earnings of ($1.54) per share and revenue of $14.37 million for the quarter. Persons that wish to register for the company's earnings conference call can do so using this link.

Sage Therapeutics Stock Down 0.4 %

Shares of NASDAQ SAGE traded down $0.03 during midday trading on Friday, reaching $7.25. 1,222,927 shares of the stock were exchanged, compared to its average volume of 2,561,201. The firm has a market cap of $443.48 million, a price-to-earnings ratio of -1.30 and a beta of 0.94. The firm has a 50-day simple moving average of $6.21 and a two-hundred day simple moving average of $7.08. Sage Therapeutics has a twelve month low of $4.62 and a twelve month high of $27.39.

Analysts Set New Price Targets

SAGE has been the topic of several analyst reports. Raymond James restated a "market perform" rating on shares of Sage Therapeutics in a research report on Thursday, October 10th. Royal Bank of Canada upgraded Sage Therapeutics from an "underperform" rating to a "sector perform" rating and set a $4.00 target price on the stock in a research report on Thursday, November 21st. Stifel Nicolaus reduced their price target on Sage Therapeutics from $10.00 to $6.00 and set a "hold" rating for the company in a report on Monday, December 16th. Scotiabank dropped their price objective on Sage Therapeutics from $17.00 to $14.00 and set a "sector outperform" rating on the stock in a report on Wednesday, October 30th. Finally, HC Wainwright restated a "neutral" rating and issued a $14.00 price objective on shares of Sage Therapeutics in a research report on Wednesday, November 20th. Three analysts have rated the stock with a sell rating, sixteen have given a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $10.53.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.